- ePoster presentation highlights findings from a new post-hoc analysis evaluating efficacy and safety of the RHA® Collection -

- Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations -

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be featured during the 2021 Virtual Skin of Color Update meeting, taking place September 10-12, 2021. The presentation highlights findings from a new post-hoc subgroup analysis evaluating the effectiveness and safety of the RHA® Collection of dermal fillers for the correction of moderate-to-severe nasolabial folds (NLFs) in patients with darker skin color.

“The RHA® Collection is the latest advancement in hyaluronic acid filler technology and we’re looking forward to sharing new data at the 2021 Virtual Skin of Color Update,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “The data presented highlights the safety and effectiveness of the RHA® Collection in treating moderate-to-severe nasolabial folds in an increasingly prominent patient population that is often underrepresented in clinical studies within aesthetic medicine. The study supports the innovation of Revance’s growing aesthetics portfolio while underscoring our commitment to proper treatment for diverse ethnicities and medical education for various skin types.”

The ePoster presentation will be available on-demand online via the Skin of Color Update website at skinofcolorupdate.com.

ePoster Presentation:

• Title: Effectiveness and safety of Resilient Hyaluronic Acid (RHA®) dermal fillers for the correction of moderate-to-severe nasolabial folds in subjects with darker skin color: post-hoc subgroup analyses of US pivotal clinical data

• Authors and Affiliations: Jay Mashburn, Kristie Kooken, Yan Liu, Revance Therapeutics, Inc., Nashville, TN

About Revance Therapeutics

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Mylan N.V. to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.

Forward Looking Statements

Any statements in this press release that are not statements of historical fact, including statements related to development of a biosimilar to BOTOX®; the potential benefits of the RHA® Collection of dermal fillers; statements about our strategy, plans and prospects, including patient population; the growth of our aesthetics portfolio; and the market opportunity for the RHA® Collection of dermal fillers and our product candidates, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate, but are not limited to: the results, timing, costs, and completion of our research and development activities and regulatory approvals, including the continuing delay in the FDA’s approval of the BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines, including as a result of observations made by the FDA during the site inspection or other reasons; the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, end user demand for our products, commercialization efforts, business operations, clinical trials and other aspects of our business and on the market; our ability to manufacture supplies for our product candidates and to acquire supplies of the RHA® Collection of dermal fillers; the uncertain clinical development process; the risk that clinical trials may not have an effective design or generate positive results; the applicability of clinical study results to actual outcomes; the rate and degree of economic benefit, the safety, efficacy, commercial acceptance and the market, competition, size and growth potential of the RHA® Collection of dermal fillers and our dug product candidates, if approved; our ability to continue to successfully commercialize the RHA® Collection of dermal fillers and fintech platform and our ability to successfully commercialize DaxibotulinumtoxinA for Injection, if approved, and the timing and cost of commercialization activities; our ability to expand sales and marketing capabilities; the status of commercial collaborations; our ability to obtain funding for our operations; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; our financial performance, including future revenue, expenses and capital requirements; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled "Risks Factors" on our Form 10-K filed with the SEC on February 25, 2021 and including, without limitation, our Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 5, 2021. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005255/en/